Sustainability Investors Products Research & Development Company Contact
Sustainability
ESG Environment Social
Investors
Reasons to invest Share information News Reports Corporate governance Stock exchange notices
Products
Salmon protein hydrolysate Salmon oil Calcium bone powder Collagen peptides European webshops
Research & Development
Our research All research programs Studies
Company
About us Our technology Operations Management Board of directors
Contact
Management Sales Investor relations
Type and search

All notices

Fourth Quarter 2019 Financial Report

07.02.2020

Signs new working capital credit line of NOK 37m

04.02.2020

MANDATORY NOTIFICATION OF TRADE

01.01.2020

ATLANTIC SAPPHIRE AS AND HOFSETH BIOCARE ASA SIGN LOI TO ESTABLISH A JOINT VENTURE IN MIAMI, US

01.11.2019

Third Quarter 2019 Financial Report

01.11.2019

STRENGHTENS MEDICAL R&D AND IR FUNCTIONS

28.10.2019

CORRECTION: ENTERS INTO A CONSULTANCY AGREEMENT WITH JAMES BERGER – CONTEMPLATED US LISTING

18.10.2019

ENTERS INTO A CONSULTANCY AGREEMENT WITH JAMES BERGER – CONTEMPLATED US LISTING

18.10.2019

CORRECTION: Second Quarter 2019 Financial Report

02.10.2019

SHARE CAPITAL INCREASE REGISTERED

01.10.2019

Previous
3 4 5
6
7 8 9
...
27
Next
Sustainability
ESG Environment Social
Investors
Reasons to invest Share information News Reports Corporate governance Stock exchange notices
Products
Salmon protein hydrolysate Salmon oil Calcium bone powder Collagen peptides European webshops
Research & Development
Our research All research programs Studies
Company
About us Our technology Operations Management Board of directors
Contact
Management Sales Investor relations

Copyright 2021 Hofseth BioCare ASA
Privacy cookies